Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.36 - $29.54 $127,776 - $194,964
-6,600 Reduced 38.6%
10,500 $203,000
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $153,090 - $197,680
7,000 Added 69.31%
17,100 $444,000
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $65,304 - $94,751
-2,400 Reduced 19.2%
10,100 $288,000
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $265,000 - $387,875
12,500 New
12,500 $382,000
Q2 2023

Aug 23, 2023

BUY
$25.16 - $41.38 $244,052 - $401,386
9,700 New
9,700 $345,000
Q4 2022

Feb 14, 2023

BUY
$28.0 - $40.56 $240,800 - $348,816
8,600 New
8,600 $349,000
Q4 2021

Feb 14, 2022

BUY
$58.09 - $82.51 $726,125 - $1.03 Million
12,500 New
12,500 $842,000
Q2 2020

Aug 13, 2020

SELL
$26.12 - $43.27 $1.91 Million - $3.16 Million
-73,000 Closed
0 $0
Q1 2020

May 11, 2020

SELL
$20.56 - $63.12 $783,336 - $2.4 Million
-38,100 Reduced 34.29%
73,000 $2.12 Million
Q4 2019

Feb 12, 2020

BUY
$28.14 - $73.01 $216,678 - $562,177
7,700 Added 7.45%
111,100 $7.13 Million
Q3 2019

Nov 14, 2019

SELL
$26.26 - $34.86 $60,398 - $80,178
-2,300 Reduced 2.18%
103,400 $2.79 Million
Q2 2019

Aug 20, 2019

BUY
$17.43 - $28.82 $1.25 Million - $2.06 Million
71,600 Added 209.97%
105,700 $2.8 Million
Q1 2019

May 15, 2019

SELL
$12.05 - $20.18 $380,780 - $637,688
-31,600 Reduced 48.1%
34,100 $626,000
Q4 2018

Feb 14, 2019

SELL
$10.74 - $19.7 $548,814 - $1.01 Million
-51,100 Reduced 43.75%
65,700 $784,000
Q3 2018

Nov 14, 2018

BUY
$14.0 - $20.3 $1.2 Million - $1.74 Million
85,600 Added 274.36%
116,800 $2.24 Million
Q1 2018

May 15, 2018

BUY
$3.72 - $7.64 $43,152 - $88,624
11,600 Added 59.18%
31,200 $225,000
Q4 2017

Feb 14, 2018

SELL
$3.14 - $4.5 $89,176 - $127,800
-28,400 Reduced 59.17%
19,600 $72,000
Q3 2017

Nov 15, 2017

BUY
$1.69 - $4.33 $81,120 - $207,840
48,000
48,000 $208,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.23B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.